Keyword: SK Biopharmaceuticals
On the heels of an FDA nod, SK Biopharmaceuticals is planning to raise about $850 million in January through a South Korean IPO, FT reports.
Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.
Drug regulators from Europe, the U.S. and Japan formed an antibiotic alliance; SK Biotek purchased an API plant by BMS; JSR nabs Selexis.
Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.